Pharma BD Deal Intelligence
Lilly takes over partner Sigilon working on cell therapies for diabetes began with 2018 Afibromer collaboration.
Lilly acquired Sigilon its cell therapy partner after initial 2018 collaboration worth $63M upfront plus $410M milestones.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Lilly licensed Sigilon's Shielded Living Therapeutics platform for Type 1 diabetes cell therapy, paying $63M upfront with up to $1.7B in milestones.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Sigilon Therapeutics Inc. (this deal) | 2018 | $1.8B | 31 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2018 deals · Eli Lilly and Company deals · Cardiovascular deals